Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib plus atezolizumab versus sorafenib in previously untreated advanced hepatocellular carcinoma
NL-OMON56004Phase 3Active, not recruiting
- Sponsor
- Exelixis, Inc.
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing Cabozantinib + atezolizumab, Sorafenib and Single-agent cabozantinib (3 arms). Primary endpoints: Progression-free survival and Overall survival. Started Aug 2019; status: active, not recruiting.
02
Drugs
cabozantinibatezolizumabsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NL-OMON56004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56004.